Just another reason to query the Daybue revenue downgrade:
Joel Beatty | Robert W. Baird Stock Analyst - TipRanks.comJoel Beatty is a 4.69-star Wall Street Analyst at Robert W. Baird. Joel Beatty's focuses on the Healthcare sector and covers 72 stocks with a 48.99% success rate
Joel Beatty has given his Buy rating due to a combination of factors surrounding ACADIA Pharmaceuticals’ financial performance and market opportunities. Despite a decrease in revenue guidance for Daybue, Beatty acknowledges the potential for this drug to be a longer-term growth opportunity. He cites the steady increase in Daybue’s revenue over the previous quarters and the management’s report that over 30% of diagnosed Rett syndrome patients in the United States had started treatment by the end of the second quarter. Additionally, the rate of discontinuations decreased, and patient growth continued, suggesting a positive trend for future sales.
Kens
Just another reason to query the Daybue revenue downgrade:Joel...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.94 |
Change
-0.290(1.79%) |
Mkt cap ! $2.034B | |||
| Open | High | Low | Value | Volume |
| $16.33 | $16.37 | $15.85 | $4.783M | 298.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 431 | $15.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.95 | 176 | 7 |
View Market Depth
| Last trade - 11.59am 13/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |